In view of the present findings of the beneficial effects of pharmacological inhibition, downstream of NRF2 signaling, in thyroid SCC tumor cells in a PDX model, and accumulating evidence of NRF2 as a central player and mediator of chemoresistance [86, 87, 88], we suggest that glutaminase inhibitor, or other drugs being developed to interfere with the KEAP1/NRF2 pathway, should be considered in clinical trials to improve the treatment of patients with advanced thyroid cancer that have an otherwise poor prognosis. This evidence concerns the gene GLS and thyroid cancer.